• Publications
  • Influence
MER-101-03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients.
Orazol weekly therapy appears to be as effective as Zometa, based on the biomarkers analyzed, and a rapid decrease for all four biomarkers was seen at seven days, and was sustained throughout the study.
Abstract B57: Safety profile of zoledronic acid in a novel oral formulation
Results to date indicate Orazol is an effective and potentially safer alternative to IV ZA, which may substantially improve patients’ quality of life.
A Comparison of Modified Food Chaining and Simultaneous Presentation Plus Nonremoval of the Spoon to Treat Food Selectivity in Children with Autism Spectrum Disorder
A multielement design is used to compare a modified version of a commonly used treatment, food chaining, and an empirically validated ABA treatment to treat the food selectivity of 2 children with autism spectrum disorder (ASD).
MER-101 tablets: A pilot bioavailability study of a novel oral formulation of zoledronic acid
A tablet dosage form of zoledronic acid has been successfully developed which will allow once weekly treatment of patients and was well tolerated and there were no serious adverse events associated with its administration.